Wall Street Zen Upgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to “Strong-Buy”

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Sunday, Wall Street Zen reports.

Several other equities research analysts also recently weighed in on IRWD. Weiss Ratings raised Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Jefferies Financial Group upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $6.23.

View Our Latest Analysis on Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Trading Up 0.4%

Shares of IRWD stock opened at $4.85 on Friday. The company’s fifty day simple moving average is $3.98 and its 200-day simple moving average is $3.96. Ironwood Pharmaceuticals has a 52 week low of $2.95 and a 52 week high of $5.78. The company has a market cap of $802.92 million, a PE ratio of 5.39 and a beta of 0.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.04. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. The business had revenue of $133.04 million for the quarter, compared to analyst estimates of $119.99 million. Equities research analysts expect that Ironwood Pharmaceuticals will post 1.10 EPS for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership boosted its position in Ironwood Pharmaceuticals by 724.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,397,242 shares of the biotechnology company’s stock valued at $11,924,000 after buying an additional 2,985,181 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Ironwood Pharmaceuticals by 529.3% during the first quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company’s stock worth $7,307,000 after acquiring an additional 1,751,219 shares during the last quarter. Pacer Advisors Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth about $3,982,000. Ritholtz Wealth Management lifted its stake in shares of Ironwood Pharmaceuticals by 130.8% in the third quarter. Ritholtz Wealth Management now owns 831,091 shares of the biotechnology company’s stock worth $3,299,000 after acquiring an additional 470,997 shares in the last quarter. Finally, First Trust Advisors LP acquired a new position in shares of Ironwood Pharmaceuticals in the third quarter worth about $2,619,000.

Ironwood Pharmaceuticals Company Profile

(Get Free Report)

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.

Further Reading

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.